The concern of generic rivalry has long loomed around copyright’s famous drug, Sildenafil, raising questions about the outlook of connected medicinal holdings. While initial years saw substantial profits, the exclusivity end has opened the door for less expensive substitutes, likely reducing revenue and creating a genuine risk for investors looki